MEDICENNA THERAPEUTICS CORP (MDNA.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:MDNA - CA58490H1073 - Common Stock
1.39 CAD
+0.02 (+1.46%)
We assign a fundamental rating of 1 out of 10 to MDNA. MDNA was compared to 23 industry peers in the Biotechnology industry. The financial health of MDNA is average, but there are quite some concerns on its profitability. MDNA is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
MDNA had negative earnings in the past year.
In the past year MDNA has reported a negative cash flow from operations.
In the past 5 years MDNA always reported negative net income.
MDNA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
MDNA has a Return On Assets of -57.51%. This is in the better half of the industry: MDNA outperforms 60.87% of its industry peers.
Looking at the Return On Equity, with a value of -89.45%, MDNA is in the better half of the industry, outperforming 69.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -57.51% | ||
| ROE | -89.45% | ||
| ROIC | N/A |
ROA(3y)-67.42%
ROA(5y)-67.89%
ROE(3y)-195.49%
ROE(5y)-148.03%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MDNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MDNA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MDNA has more shares outstanding
MDNA has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -1.24, we must say that MDNA is in the distress zone and has some risk of bankruptcy.
MDNA has a better Altman-Z score (-1.24) than 69.57% of its industry peers.
MDNA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.01, MDNA belongs to the top of the industry, outperforming 82.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.24 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
MDNA has a Current Ratio of 4.94. This indicates that MDNA is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 4.94, MDNA is doing good in the industry, outperforming 78.26% of the companies in the same industry.
A Quick Ratio of 4.94 indicates that MDNA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.94, MDNA is in the better half of the industry, outperforming 78.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.94 | ||
| Quick Ratio | 4.94 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 54.05% over the past year.
EPS 1Y (TTM)54.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, MDNA will show a very negative growth in Earnings Per Share. The EPS will decrease by -46.60% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-73.4%
EPS Next 2Y-53.72%
EPS Next 3Y-46.6%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MDNA. In the last year negative earnings were reported.
Also next year MDNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as MDNA's earnings are expected to decrease with -46.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-53.72%
EPS Next 3Y-46.6%
5. Dividend
5.1 Amount
MDNA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:MDNA (11/21/2025, 7:00:00 PM)
1.39
+0.02 (+1.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners6.32%
Inst Owner ChangeN/A
Ins Owners14.23%
Ins Owner ChangeN/A
Market Cap115.94M
Revenue(TTM)N/A
Net Income(TTM)-13.10M
Analysts82
Price Target3.58 (157.55%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)57.52%
Min EPS beat(2)-17.65%
Max EPS beat(2)132.68%
EPS beat(4)2
Avg EPS beat(4)32.6%
Min EPS beat(4)-17.65%
Max EPS beat(4)132.68%
EPS beat(8)5
Avg EPS beat(8)-9.59%
EPS beat(12)9
Avg EPS beat(12)9.13%
EPS beat(16)12
Avg EPS beat(16)10.73%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)34.28%
PT rev (3m)-2.59%
EPS NQ rev (1m)2.57%
EPS NQ rev (3m)2.57%
EPS NY rev (1m)-4.08%
EPS NY rev (3m)7.83%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-50%
Revenue NY rev (3m)-50%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 7.92 | ||
| P/tB | 7.95 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.17
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0
BVpS0.18
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -57.51% | ||
| ROE | -89.45% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-67.42%
ROA(5y)-67.89%
ROE(3y)-195.49%
ROE(5y)-148.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 2.99% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.94 | ||
| Quick Ratio | 4.94 | ||
| Altman-Z | -1.24 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
EPS Next Y-73.4%
EPS Next 2Y-53.72%
EPS Next 3Y-46.6%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-28.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.15%
OCF growth 3YN/A
OCF growth 5YN/A
MEDICENNA THERAPEUTICS CORP / MDNA.CA FAQ
Can you provide the ChartMill fundamental rating for MEDICENNA THERAPEUTICS CORP?
ChartMill assigns a fundamental rating of 1 / 10 to MDNA.CA.
What is the valuation status for MDNA stock?
ChartMill assigns a valuation rating of 0 / 10 to MEDICENNA THERAPEUTICS CORP (MDNA.CA). This can be considered as Overvalued.
What is the profitability of MDNA stock?
MEDICENNA THERAPEUTICS CORP (MDNA.CA) has a profitability rating of 1 / 10.